文献速递临床试验与 GCP真实世界研究与卫生经济

连续血糖监测对基础胰岛素治疗2型糖尿病患者血糖控制的影响:一项随机临床试验

Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

这项在美国15个中心开展的随机临床试验纳入175例接受基础胰岛素治疗但未用餐时胰岛素的2型糖尿病成人患者,按2:1随机分配至连续血糖监测(CGM)组或传统血糖仪(BGM)组。

要点

  • CGM较BGM显著降低HbA1c达0.4%,目标范围时间增加15%。
  • CGM组血糖>250 mg/dL时间比例显著低于BGM组(11% vs 27%)。
  • 严重低血糖事件两组均罕见(CGM组1%,BGM组2%)。

核心结论

  • 在接受基础胰岛素治疗但未用餐时胰岛素的血糖控制不佳的2型糖尿病成人中,CGM较BGM在8个月时显著降低HbA1c水平。

研究设计与样本

  • 随机临床试验,在美国15个中心开展,纳入175例接受基础胰岛素治疗但不使用餐时胰岛素的2型糖尿病成人,按2:1随机分配至CGM组(n=116)或BGM组(n=59)。

主要发现

  • 严重低血糖事件:CGM组1例(1%),BGM组1例(2%)。

临床怎么用

  • 对于接受基础胰岛素治疗但未用餐时胰岛素的血糖控制不佳的2型糖尿病成人,可考虑使用CGM以改善血糖控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Continuous glucose monitoring (CGM) has been shown to be beneficial for adults with type 2 diabetes using intensive insulin therapy, but its use in type 2 diabetes treated with basal insulin without prandial insulin has not been well studied. OBJECTIVE: To determine the effectiveness of CGM in adults with type 2 diabetes treated with basal insulin without prandial insulin in primary care practices. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted at 15 centers in the US (enrollment from July 30, 2018, to October 30, 2019; follow-up completed July 7, 2020) and included adults with type 2 diabetes receiving their diabetes care from a primary care clinician and treated with 1 or 2 daily injections of long- or intermediate-acting basal insulin without prandial insulin, with or without noninsulin glucose-lowering medications. INTERVENTIONS: Random assignment 2:1 to CGM (n = 116) or traditional blood glucose meter (BGM) monitoring (n = 59). MAIN OUTCOMES AND MEASURES: The primary outcome was hemoglobin A1c (HbA1c) level at 8 months. Key secondary outcomes were CGM-measured time in target glucose range of 70 to 180 mg/dL, time with glucose level at greater than 250 mg/dL, and mean glucose level at 8 months. RESULTS: Among 175 randomized participants (mean [SD] age, 57 [9] years; 88 women [50%]; 92 racial/ethnic minority individuals [53%]; mean [SD] baseline HbA1c level, 9.1% [0.9%]), 165 (94%) completed the trial. Mean HbA1c level decreased from 9.1% at baseline to 8.0% at 8 months in the CGM group and from 9.0% to 8.4% in the BGM group (adjusted difference, -0.4% [95% CI, -0.8% to -0.1%]; P = .02). In the CGM group, compared with the BGM group, the mean percentage of CGM-measured time in the target glucose range of 70 to 180 mg/dL was 59% vs 43% (adjusted difference, 15% [95% CI, 8% to 23%]; P < .001), the mean percentage of time at greater than 250 mg/dL was 11% vs 27% (adjusted difference, -16% [95% CI, -21% to -11%]; P < .001), and the means of the mean glucose values were 179 mg/dL vs 206 mg/dL (adjusted difference, -26 mg/dL [95% CI, -41 to -12]; P < .001). Severe hypoglycemic events occurred in 1 participant (1%) in the CGM group and in 1 (2%) in the BGM group. CONCLUSIONS AND RELEVANCE: Among adults with poorly controlled type 2 diabetes treated with basal insulin without prandial insulin, continuous glucose monitoring, as compared with blood glucose meter monitoring, resulted in significantly lower HbA1c levels at 8 months. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03566693.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Martens T, Beck RW, Bailey R, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. JAMA. 2021. PMID: 34077499. doi:10.1001/jama.2021.7444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。